Treatment continuation in patients receiving biological agents or conventional DMARD therapy

A Zink, J Listing, S Kary, P Ramla, M Stoyanova-Schalz, K Babinsky, U von Hinueber, E Gromnica-Ihle, S Wassenberg, C Antoni, P Herzer, J Kekow, M Schneider, R Rau

Objective: To compare drug continuation rates in patients with rheumatoid arthritis who start on a biological agent and in a control group of patients with a change in disease modifying antirheumatic drug (DMARD) treatment after previous DMARD failure.

Methods: Patients with rheumatoid arthritis enrolled in the German biologics register between May 2001 and September 2003 were included in the study. Data were available for 511 patients treated with etanercept, 343 with infliximab, 70 with anakinra, and 599 controls. Propensity scores were used to select a subsample of patients from the control group who were likely to be treated with biological agents because of their disease severity, as well as comparable infliximab and etanercept cases.

Results: Treatment continuation after 12 months was similar for etanercept (68.6% (95% confidence interval, 62% to 75%)) and infliximab (65.4% (58% to 73%)) but lower for anakinra (59% (41% to 77%)). Treatment continuation was more likely for patients on combinations of biological agents and DMARDs than for those on infliximab or etanercept alone. Patients treated with biological agents were more severely ill than those in the control group and had more previous DMARD failures. After adjustment for baseline differences, the continuation rates were higher in patients treated with biological agents than in comparable control patients treated with leflunomide or leflunomide/methotrexate.

Conclusions: Treatment continuation of biological agents in clinical practice is less likely than in randomised clinical trials but more likely than in comparable controls treated with conventional DMARDs.

Cytokine inhibitors have opened up new and promising treatment options in rheumatoid arthritis. Randomised clinical trials have demonstrated the efficacy of cytokine inhibitors in reducing inflammation as well as in inhibiting joint destruction in active rheumatoid arthritis, particularly in patients not responding to conventional disease modifying antirheumatic drugs (DMARDs).1-5

Although trial based evidence and clinical experience to date are encouraging, there is still insufficient information on the long term safety and continuing efficacy of biological agents in the general population with rheumatoid arthritis and in high risk patient groups (for example, patients with serious comorbidity). Concerns have been raised over the risk of reactivation of tuberculosis, an increase in other severe infections, and rare but serious events such as drug induced lupus or demyelinating disease, as well as the unknown risk of malignancies.

Long term observational studies on patients treated with biological agents have various specific strengths. They represent the full spectrum of patients undergoing treatment, including those who would be excluded from clinical trials owing to severe comorbidity. They allow comparison of different treatments and treatment regimens (including off-label use) within a single study, and—because of their long term approach—they present the outcomes of exposure to multiple drugs (given concomitantly or subsequently). Additionally, they provide information on the cost-effectiveness of new treatments in real life clinical practice.

Various European countries have established long term registers of patients treated with biological agents. The German register has enrolled an inherent control group which consists of patients with a change of conventional DMARD therapy because of inadequate disease control or poor tolerability of at least one previous DMARD. These patients have been followed up with the same protocol as the patients treated with biological agents. This will allow us to compare the results in the biologics groups with the overall risks of the disease and its present treatment.

In this paper we address the following questions. First, what is the baseline clinical status of patients starting on a biological treatment for the first time in Germany, compared with a control group of patients with at least one failure on conventional DMARD therapy? Second, what is the drug continuation rate over the first 12 months in patients receiving the various biological agents and in the subsamples of the control group?

We report data from the German biologics register for patients enrolled up to 1 September 2003. At that point, data were available in the biological agents group for patients initially treated with etanercept, infliximab, or anakinra. Patients in the adalimumab group are not included in this analysis owing to the later start of enrolment.

METHODS

Background
In 2001, the German Society of Rheumatology issued a guideline on the prescription of biological treatments, recommending that patients who have failed to respond to or have not tolerated at least two DMARDs, including methotrexate, should be treated with cytokine inhibitors. In conjunction with this recommendation, the German Society of Rheumatology invited all rheumatologists to contribute to...

Abbreviations: DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; FFBH, Hannover functional status questionnaire; SJC, swollen joint count; TJC, tender joint count
Table 1 Baseline characteristics of patients receiving biological agents and of the control groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Biological agents</th>
<th>Infliximab</th>
<th>Etanercept</th>
<th>Anakinra</th>
<th>Total</th>
<th>Leflunomide only</th>
<th>Leflunomide + methotrexate</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>511</td>
<td>343</td>
<td>70</td>
<td></td>
<td>599</td>
<td>120</td>
<td>141</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.7 (12.6)</td>
<td>53.6 (12.6)</td>
<td>54.3 (11.6)</td>
<td></td>
<td>56.5 (11.4)</td>
<td>58.0 (11.1)</td>
<td>57.4 (11.2)</td>
</tr>
<tr>
<td>Female</td>
<td>77.9%</td>
<td>71.1%</td>
<td>77.1%</td>
<td>77.1%</td>
<td>78.0%</td>
<td>78.0%</td>
<td>78.0%</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>9.0 (5.0 to 16.5)</td>
<td>8.5 (4.0 to 14.0)</td>
<td>10.2 (6.3)</td>
<td></td>
<td>10.0 (6.6)</td>
<td>10.6 (6.3)</td>
<td>10.9 (6.9)</td>
</tr>
<tr>
<td>Rheumatoid factor positive</td>
<td>80.6%</td>
<td>79.0%</td>
<td>91.2%</td>
<td>77.1%</td>
<td>82.5%</td>
<td>85.8%</td>
<td>78.0%</td>
</tr>
<tr>
<td>Erosive disease</td>
<td>87.4%</td>
<td>87.4%</td>
<td>91.2%</td>
<td>75.0%</td>
<td>85.8%</td>
<td>78.0%</td>
<td>78.0%</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>10.4 (6.3)</td>
<td>10.7 (6.5)</td>
<td>12.6 (7.1)</td>
<td></td>
<td>10.6 (6.3)</td>
<td>13.0 (7.0 to 22.0)</td>
<td>7.0 (3.0 to 12.0)</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>34.0 (20.0 to 54.0)</td>
<td>35.0 (17.0 to 58.0)</td>
<td>37.0 (18.5 to 56.0)</td>
<td></td>
<td>28.0 (16.0 to 44.0)</td>
<td>28.0 (16.0 to 44.0)</td>
<td>26.0 (16.0 to 40.0)</td>
</tr>
<tr>
<td>SJC</td>
<td>20.0 (7.0 to 44.0)</td>
<td>20.0 (8.0 to 50.0)</td>
<td>21.0 (8.1 to 35.5)</td>
<td></td>
<td>14.0 (7.0 to 24.0)</td>
<td>14.0 (7.0 to 24.0)</td>
<td>12.0 (5.0 to 28.1)</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>6.1 (1.2)</td>
<td>6.0 (1.2)</td>
<td>6.1 (1.2)</td>
<td></td>
<td>6.1 (1.2)</td>
<td>5.5 (1.2)</td>
<td>5.6 (1.1)</td>
</tr>
<tr>
<td>FFbH</td>
<td>52.8 (23.4)</td>
<td>53.8 (21.6)</td>
<td>52.2 (24.2)</td>
<td></td>
<td>50.8 (23.0)</td>
<td>51.9 (21.2)</td>
<td>60.4 (21.8)</td>
</tr>
<tr>
<td>Number of previous DMARDs</td>
<td>3.9 (1.7)</td>
<td>3.7 (1.7)</td>
<td>4.2 (2.0)</td>
<td></td>
<td>3.7 (1.7)</td>
<td>4.2 (2.0)</td>
<td>2.2 (1.2)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>91.2%</td>
<td>92.1%</td>
<td>78.6%</td>
<td></td>
<td>91.2%</td>
<td>92.1%</td>
<td>90.7%</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>72.5%</td>
<td>66.6%</td>
<td>78.6%</td>
<td></td>
<td>72.5%</td>
<td>66.6%</td>
<td>78.0%</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>61.9%</td>
<td>59.8%</td>
<td>62.9%</td>
<td></td>
<td>61.9%</td>
<td>59.8%</td>
<td>61.5%</td>
</tr>
<tr>
<td>Antimalorals</td>
<td>45.4%</td>
<td>43.7%</td>
<td>52.9%</td>
<td></td>
<td>45.4%</td>
<td>43.7%</td>
<td>45.4%</td>
</tr>
<tr>
<td>Parenteral gold</td>
<td>36.9%</td>
<td>36.7%</td>
<td>52.9%</td>
<td></td>
<td>36.9%</td>
<td>36.7%</td>
<td>36.9%</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>21.8%</td>
<td>18.5%</td>
<td>28.6%</td>
<td></td>
<td>21.8%</td>
<td>18.5%</td>
<td>21.8%</td>
</tr>
<tr>
<td>Ciclosporine A</td>
<td>20.8%</td>
<td>18.2%</td>
<td>22.9%</td>
<td></td>
<td>20.8%</td>
<td>18.2%</td>
<td>20.8%</td>
</tr>
<tr>
<td>Other</td>
<td>12.6%</td>
<td>9.1%</td>
<td>11.4%</td>
<td></td>
<td>12.6%</td>
<td>9.1%</td>
<td>12.6%</td>
</tr>
<tr>
<td>Biological agents ever</td>
<td>9.2%</td>
<td>16.4%</td>
<td>30.0%</td>
<td></td>
<td>9.2%</td>
<td>16.4%</td>
<td>9.2%</td>
</tr>
</tbody>
</table>

Variables are mean (SD), median (interquartile range), of per cent. 
DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FFbH, Hannover functional status questionnaire; IQR, interquartile range.
assessment questionnaire (HAQ), and scores can be transformed from one questionnaire to the other. The disease activity score based on 28 joint counts (DAS28) was calculated. The case report forms were sent by fax to the study centre. Queries were sent back in the case of incomplete or inconsistent data. The minimum valid data asked for in every case included the baseline characteristics, and at follow up the start and end of DMARD or biological treatment, reasons for treatment termination, and detailed descriptions of adverse events.

Statistics
The $\chi^2$ test and the non-parametric Kruskal–Wallis test were used to compare the baseline characteristics of the patients. The Kaplan–Meier method was applied to calculate the probability of treatment continuation. Three of these survival analyses were carried out for each drug. The first analysis considered treatment termination overall, resulting from adverse events, lack of efficacy, or miscellaneous causes such as non-compliance. In the second analysis, only those treatment terminations were considered where adverse events were cited as at least one reason for stopping. In the third analysis, the same procedure was followed for lack of efficacy. Treatment terminations resulting from partial remission were calculated as censored data. Only the continuation of the new treatment applied at study entry was investigated; subsequent treatment episodes were not considered. Different Kaplan–Meier curves were compared using the log-rank test. The corresponding 95% confidence intervals (CI) of the continuation rates were estimated by the Hall–Wellner method. Cox proportional hazard models were used to investigate the effect of all possible risk factors on treatment duration (number of previous DMARDs, rheumatoid factor, DAS28, SJC, TJC, FFbH, disease duration, age, and sex).

As patients in the control group and those in the biological agents groups differed significantly in their baseline characteristics, propensity scores were calculated in order to select a more comparable subgroup of patients from the control group. Multivariate logistic regression was applied to estimate the likelihood (propensity score) of being treated with tumour necrosis factor (TNF) inhibitors (infliximab or etanercept). The following baseline characteristics were included in the multivariate logistic regression analysis: age, number of previous DMARDs, DAS28, and FFbH. Each of these variables discriminated significantly between cases and controls. Twenty seven of 120 patients treated at study entry with leflunomide alone and 21 of 141 patients treated with leflunomide and methotrexate but only six of 121 patients treated with methotrexate alone fulfilled the criterion of a propensity score $>50$% of being treated with TNF inhibitors. We therefore used the 48 patients from the leflunomide subgroups as fulfilling the above mentioned criterion for the comparisons.

RESULTS
Between 1 May 2001 and 1 September 2003, 1523 patients from 109 centres were entered into the RABBIT database. In this population, 599 patients had a change in their conventional DMARD therapy (control group), and 511 patients started treatment with etanercept, 343 with infliximab, and 70 with anakinra.

Patient characteristics
Table 1 shows the baseline clinical status of patients treated with the individual biological drugs compared with patients in the control group. Two large subgroups of the control group (leflunomide alone or leflunomide plus methotrexate) are shown separately. In patients treated with biological agents, the mean age in all groups was 54 years and mean disease duration ranged from 9 to 13 years. The patients had very active disease, with a mean of more than 10 swollen joints and raised ESR and C reactive protein. DAS28 and functional status were similar in the biologics groups. Patients in all three groups had a long treatment history with DMARDs. The vast majority had been treated with methotrexate before, and about three quarters with leflunomide. Other DMARDs such as sulfasalazine or antimalarials had been tried in a large number of patients, leading to an average number of previous DMARDs of 3.9 to 4.2.

Patients in the control group had significantly shorter disease duration ($p<0.001$), a lower prevalence of erosive disease, and a lower mean DAS28 (5.4 vs 6.0 and 6.1, $p<0.001$) than those in the biological agents groups. Patients treated with leflunomide or leflunomide/methotrexate had a greater number of previous DMARD failures ($p<0.001$), a higher DAS28 ($p = 0.002$), and a higher prevalence of erosive disease ($p = 0.001$) than the other patients in the control group. Thus they were more suitable than the rest of the control group in terms of comparability with the patients in the biological agents groups.

The major difference between the biological agents group and the control group was the number of previous DMARD failures: patients receiving biological agents had almost twice

### Table 2: Current prescription of DMARDs in patients receiving biologics and in the control groups

<table>
<thead>
<tr>
<th>DMARDs currently (%)</th>
<th>Etanercept</th>
<th>Infliximab</th>
<th>Anakinra</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>No DMARD</td>
<td>49.7</td>
<td>10.5</td>
<td>30.0</td>
<td>NA</td>
</tr>
<tr>
<td>Methotrexate alone</td>
<td>32.7</td>
<td>63.8</td>
<td>60.0</td>
<td>20.2</td>
</tr>
<tr>
<td>Leflunomide alone</td>
<td>7.8</td>
<td>13.4</td>
<td>5.7</td>
<td>20.0</td>
</tr>
<tr>
<td>Other single therapy</td>
<td>3.3</td>
<td>1.7</td>
<td>1.4</td>
<td>4.7</td>
</tr>
<tr>
<td>Combination methotrexate + leflunomide</td>
<td>1.8</td>
<td>3.8</td>
<td>1.4</td>
<td>23.5</td>
</tr>
<tr>
<td>Other combination of 2 DMARDs</td>
<td>3.5</td>
<td>4.7</td>
<td>1.4</td>
<td>24.0</td>
</tr>
<tr>
<td>Combination of 3 DMARDs</td>
<td>1.2</td>
<td>2.0</td>
<td>0.0</td>
<td>7.5</td>
</tr>
</tbody>
</table>

DMARD, disease modifying antirheumatic drug; NA, not assessed.
as many DMARD failures on average. Most had previous experience with methotrexate plus a variety of other DMARDs. In addition, only 1.4–4.2% of the patients in the control group had been treated with a biological agent previously, compared with 30% of those receiving anakinra, 16.4% of those receiving infliximab, and 9.2% of those receiving etanercept.

**DMARD therapy in combination with a biological agent**

Although infliximab is approved for use in combination with methotrexate, 10.5% of the patients were treated with infliximab alone at study entry and approximately one quarter of the patients were treated with infliximab in combination with another DMARD (table 2). More than half the etanercept patients were treated concomitantly with conventional DMARDs. In 6.7% of the infliximab patients and 4.7% of the etanercept patients, two or more DMARDs were prescribed in addition to the biological agent.

**Treatment continuation**

Similar drug continuation rates were found for etanercept (69% (95% CI, 62% to 75%)) and infliximab (65% (58% to 73%)) for the first 12 months of observation (fig 1). The continuation rate for anakinra (59% (41% to 77%)) were significantly lower (p = 0.004 anakinra v etanercept; p = 0.03 anakinra v infliximab).

Predictors of premature treatment termination were the number of previous DMARDs (hazard ratio (HR) = 1.09 (95% CI, 1.01 to 1.18)), rheumatoid factor (HR = 1.53 (1.09 to 2.16)), and greater age (HR = 1.01 (1.00 to 1.02)) but not DAS28, TJC, or SJC at baseline.

The drug continuation rates for etanercept in combination with methotrexate or another DMARD tended to be higher (p = 0.11 and p = 0.07) than for etanercept alone (table 3). In the infliximab group this difference between single and combination therapy was even more apparent. Following adjustment for risk factors of premature treatment termination mentioned above, the hazard ratio of treatment termination for infliximab alone in comparison to infliximab/methotrexate was 1.9 (95% CI, 1.1 to 3.1). For etanercept alone versus etanercept/DMARD the HR was 1.3 (0.9 to 1.8).

Reasons for treatment termination were specified by the rheumatologist in nearly all cases (288/290) where treatment with a biological agent was discontinued. In 28 cases (12 with infliximab, 13 with etanercept, and one with anakinra, 16.4% of those receiving anakinra, 16.4% of those receiving infliximab, and 9.2% of those receiving etanercept.

**DMARD therapy in combination with a biological agent**

Although infliximab is approved for use in combination with methotrexate, 10.5% of the patients were treated with infliximab alone at study entry and approximately one quarter of the patients were treated with infliximab in combination with another DMARD (table 2). More than half the etanercept patients were treated concomitantly with conventional DMARDs. In 6.7% of the infliximab patients and 4.7% of the etanercept patients, two or three DMARDs were prescribed in addition to the biological agent.

**Treatment continuation**

Similar drug continuation rates were found for etanercept (69% (95% CI, 62% to 75%)) and infliximab (65% (58% to 73%)) for the first 12 months of observation (fig 1). The continuation rate for anakinra (59% (41% to 77%)) were significantly lower (p = 0.004 anakinra v etanercept; p = 0.03 anakinra v infliximab).

Predictors of premature treatment termination were the number of previous DMARDs (hazard ratio (HR) = 1.09 (95% CI, 1.01 to 1.18)), rheumatoid factor (HR = 1.53 (1.09 to 2.16)), and greater age (HR = 1.01 (1.00 to 1.02)) but not DAS28, TJC, or SJC at baseline.

The drug continuation rates for etanercept in combination with methotrexate or another DMARD tended to be higher (p = 0.11 and p = 0.07) than for etanercept alone (table 3). In the infliximab group this difference between single and combination therapy was even more apparent. Following adjustment for risk factors of premature treatment termination mentioned above, the hazard ratio of treatment termination for infliximab alone in comparison to infliximab/methotrexate was 1.9 (95% CI, 1.1 to 3.1). For etanercept alone versus etanercept/DMARD the HR was 1.3 (0.9 to 1.8).

Reasons for treatment termination were specified by the rheumatologist in nearly all cases (288/290) where treatment with a biological agent was discontinued. In 28 cases (12 with infliximab, 13 with etanercept, and one with anakinra, 16.4% of those receiving anakinra, 16.4% of those receiving infliximab, and 9.2% of those receiving etanercept.
DMARDs, there was a significantly increased hazard ratio for age, rheumatoid factor, and number of previous treatment terminations into account. Following adjustment lower treatment continuation rates (64.1% after six months, 50%) differed significantly only in terms of the numbers of patients treated with a biological agent, based on their clinical status at study entry. These patients had baseline characteristics similar to 563 patients treated with TNF inhibitors (etanercept n = 350, infliximab n = 213) who also met the criterion of a propensity score >50% (table 4). The two groups differed significantly only in terms of the numbers of previous DMARDs (4.6 v 3.9).

Nevertheless, the patients in the leflunomide subgroup had lower treatment continuation rates (64.1% after six months, 51.0% after 12 months) than patients receiving TNF inhibitors (fig 2, p = 0.058). This result was confirmed in a Cox regression analysis, taking risk factors for premature treatment termination into account. Following adjustment for age, rheumatoid factor, and number of previous DMARDs, there was a significantly increased hazard ratio of 1.7 (p = 0.025) for treatment termination with leflunomide in comparison with infliximab/etanercept.

**DISCUSSION**

Even though rheumatologists today have access to far more effective drugs than they did a decade ago, a cure remains elusive and all available agents have to be given continuously in order to suppress inflammation and joint destruction. It is known that a majority of patients respond well to methotrexate therapy, which has high drug continuation rates. However, if methotrexate alone is insufficient or not tolerated, other therapeutic options have to be chosen. Much less is known about the long term continuation of the new drugs which are given in the risk group of patients with methotrexate failure.

The aim of this study was to compare treatment continuation rates of patients with rheumatoid arthritis treated in daily rheumatological practice with one of the cytokine inhibitors etanercept, infliximab, or anakinra or with leflunomide or a combination of methotrexate and leflunomide over the first 12 months. In order to select controls as similar as possible to the patients treated with biological agents, attention was focused exclusively on those patients in the control group who needed more effective therapy than methotrexate alone or who had intolerance to methotrexate.

Not unexpectedly, drug continuation over one year in our observational data was lower than in the major randomised clinical trials. In the ATTRACT trial drug continuation of infliximab plus methotrexate was 73%. The TEMPO trial showed drug continuation of 76% for etanercept alone and 84% for etanercept plus methotrexate. For anakinra, drug continuation over 24 weeks was 78% in the 1 mg/kg/day group in the study by Cohen et al. Leflunomide alone had a drug continuation rate of 80% over 24 weeks in the study by Dougados et al and 77% in the study by Kremer et al. One possible explanation for the higher treatment continuation in clinical trials relates to the nature of the trials themselves and the wish of both the investigator and the patient to persist, whereas in normal clinical practice they may decide to stop the drug or to change over.

The most important risk factor for treatment termination in our data was a large number of previous treatment failures. Two or more treatment failures have not been used as an inclusion criterion in clinical trials but are a cue for starting biological therapy in clinical practice. Thus the differences compared with clinical trials are not surprising because our data reflect routine day to day care in contrast to randomised trials with their rigorous protocols and restricted patient inclusion criteria. Reports from everyday rheumatology practice reveal data that resemble our own findings far more closely than those from randomised trials. In the Netherlands, Flendrie et al found one year drug continuation rates of 66% for infliximab and 74% for etanercept in patients treated with a biological agent for the first time; these findings are very similar to our data for infliximab (65%) and higher than those for etanercept (69% in our study). Chung et al reported a one year continuation rate for infliximab of 71% from an inception cohort in Canada, and this compares well with our data. The higher efficacy of etanercept in combination with methotrexate than of etanercept alone reported by van Vollenhoven et al from the Stockholm TNFα registry is in agreement with our finding of higher continuation rates in etanercept combination therapy.

It has to be born in mind that treatment cessation is subject to within-physician variation. This is especially true for the reasons given in patients who experienced a relative lack of efficacy as well as an adverse drug reaction. Thus the total treatment continuation rates are more important than the rates for the various reasons. Furthermore, it is relevant that the physicians enrolled patients for all groups simultaneously. This allows comparisons between patients treated with infliximab or etanercept and those receiving conventional DMARD if the differences in the patient characteristics are taken into account.

![Figure 2](https://example.com/image.png) Probability of treatment continuation in patients with an increased likelihood of being treated with tumour necrosis factor (propensity score >50%).
Geborek et al. found very low drug continuation rates for leflunomide of about 40% after 12 months in a comparable register of patients with previous DMARD failures; our data indicated relatively better performance for leflunomide. However, after controlling for disease severity and other factors influencing drug continuation, the TNF inhibitors in our data had higher continuation rates than leflunomide. The comparison of treatment continuation in patients treated with leflunomide or leflunomide/methotrexate on the one hand and TNF inhibitors on the other using the propensity score method showed that adjustment for background risk is essential in order to put treatment results into context. However, our results need further confirmation as they are based only on a rather small number of control patients.

Conclusions
This study is the first to show data on treatment continuation with various combinations of biological agents and conventional DMARDs. The data suggest that combination of both etanercept and infliximab with DMARDs such as methotrexate or leflunomide leads to higher treatment continuation. However, the data on combination with leflunomide or other DMARDs require confirmation by longer observation in the register and by other observational studies.

ACKNOWLEDGEMENTS
RABBIT is supported by an unconditional, joint grant from Essex Pharma (since 2001), Wyeth Pharma (since 2001), Amgen (since 1/2001), and Abbott (since 9/2003).

We wish to thank those rheumatologists who enrolled large numbers of cases (30 or more each): A Kapelle, Hoyerwynda; W Demary, Hildesheim; G-R Burmester, Berlin; K Rockwitz, Göttingen; E Edelmann, Bad Aibling; E Wilden, Cologne; T Karger, Cologne; H-E Schroeder, Dresden; T Klopsch, Neubrandenburg; R Dockhorn, Wener; A Graessler, Pirna; K Krueger, Munich; W Liman, Hagen; H Soerensen, Berlin; WL Gross, Lübeck/Bad Bramstedt. We thank U Kamenz and K Peters for their careful monitoring of the study.

Authors’ affiliations
A Zink, J Listing, S Kary, P Ramlau, German Rheumatism Research Centre, Berlin, Germany
M Stoyanova-Scholz, Department of Rheumatology, Klinikum Duisburg, Essen, Germany
K Babinsky, Practising rheumatologist, Halle, Germany
U von Hinüber, Practising rheumatologist, Hildesheim, Germany
E Gronimca-Ille, Rheumaklinik Berlin-Buch, Berlin, Germany
S Wassenberg, Evangelisches Fachkrankenhaus, Ratingen, Germany
C Antoni, Institute for Clinical Immunology and Rheumatology, University of Erlangen, Erlangen, Germany
P Herzer, Practising rheumatologist, Munich, Germany
J Kekow, Clinic for Rheumatology, University of Magdeburg, Magdeburg, Germany
M Schneider, Department of Rheumatology, Heinrich Heine University, Duesseldorf, Germany
R Rau, Ev Fachkrankenhaus, Ratingen, Germany

REFERENCES